Health · 243 articles Page 3/5
- Bundibugyo Ebola Outbreak Confirmed in Democratic Republic of the Congo With 28 Cases as WHO Mobilizes ResponseThe World Health Organization and the Africa Centres for Disease Control and Prevention confirmed a recognized outbreak of Bundibugyo ebolavirus across the Democratic Republic of the Congo on…
- Johnson & Johnson Reports Positive Phase 2 Nipocalimab Data Demonstrating Saliva Production Gains in Sjögren's DiseaseJohnson & Johnson released clinical outcome findings from its Phase 2 DAHLIAS trial evaluating investigational FcRn blocker nipocalimab in adults living with moderate-to-severe Sjögren's disease.
- FDA Approves Intravenous and Subcutaneous Atezolizumab for Stage III dMMR Colon Cancer Adjuvant TreatmentThe United States Food and Drug Administration finalized broad regulatory approval notices between November 6 and 8.
- NYU Langone Heart Presents Landmark Cardiovascular Findings on Chronic Kidney Disease at AHA Scientific Sessions 2026Cardiologists from the Leon H. Charney Division of Cardiology at NYU Langone Health presented findings on November 7 during the American Heart Association Scientific Sessions 2026 in Chicago.
- FDA Grants Priority Review for uniQure's AMT-130 Gene Therapy in Huntington's DiseaseBiopharmaceutical developer uniQure N.V. submitted a Form 8-K filing to the U.S. Securities and Exchange Commission confirming that the Food and Drug Administration accepted its Biologics License…
- Ivonescimab Achieves 50.7% Pathological Complete Response in Resectable Lung Cancer TrialBiotechnology firm Akeso, Inc. (9926.HK) released updated findings from a prospective Phase II clinical trial on November 6, 2026, evaluating its first-in-class bispecific antibody ivonescimab…
- Guardant Health Q3 Revenue Rises 36% as Shield Blood Test Volume Surges 246% to 83,000Precision oncology and liquid biopsy innovator Guardant Health, Inc. (NASDAQ: GH) announced third-quarter financial results for fiscal 2026 on November 5, 2026, delivering substantial commercial…
- Edgewise Therapeutics Advances EDG-7500 into Phase 3 STRATUS-HCM with Echo-Free Dosing ProtocolClinical-stage biopharmaceutical company Edgewise Therapeutics, Inc. (NASDAQ: EWTX) announced on November 5, 2026, the successful completion of an End-of-Phase 2 regulatory meeting with the United…
- argenx Announces Positive Phase 3 ALKIVIA Results for Efgartigimod in Autoimmune Myositis with sBLA Planned in 2026Biotechnology enterprise argenx SE officially presented landmark positive topline results on November 7, 2026, from its pivotal global Phase 3 ALKIVIA registrational study evaluating subcutaneous…
- Johnson & Johnson Reports Positive Phase 3 ICONIC-PsA 1 Trial Data for Oral Peptide ICOTYDE in Active Psoriatic ArthritisClinical Protocol Metrics and Endpoint Outcomes from the ICONIC-PsA 1 Trial Enrolled Patient Cohort & Stratification: 552 Biologic-Naive Adults with Active PsA Week 16 Primary Efficacy Endpoint…
- Eli Lilly Expands Partnership with Hims & Hers to Distribute FDA-Approved Branded Medicines OnlineGlobal pharmaceutical leader Eli Lilly and Company announced a major commercial expansion with personalized digital health platform Hims & Hers Health on November 6, 2026, broadening…
- Marathon Petroleum Inks $4.2 Billion Deal to Sell Minnesota and North Dakota Refineries to CVR EnergyDownstream energy giant Marathon Petroleum Corporation announced a definitive asset purchase agreement with Texas-based refiner CVR Energy on November 6, 2026, transferring key refining and…
- Swinburne University Study Confirms Broccoli Compound Sulforaphane Restores Frataxin to Treat Friedreich AtaxiaNeuroscience investigators from Swinburne University of Technology in Melbourne announced a major therapeutic milestone on November 7, 2026, confirming that sulforaphane—a natural phytochemical…
- Swiss Biotech iOnctura Unveils SITC 2026 Data on Roginolisib Overcoming Immunotherapy Resistance in Lung CancerSwiss clinical-stage oncology biopharmaceutical developer iOnctura announced breakthrough multi-center Ib/II clinical trial results at the 41st Annual Meeting of the Society for Immunotherapy of…
- US State Attorneys General Secure Up to $10M Settlement in Perry Johnson Medical Data BreachAttorneys general from New York, New Jersey, Connecticut, and Michigan formally announced a comprehensive multi-state settlement on November 6, 2026, resolving enforcement investigations into medical…
- Novo Nordisk Reports Real-World AASLD 2026 Clinical Data Demonstrating 63% MASH Resolution for Semaglutide 2.4 mg Outperforming ResmetiromKey Comparative Clinical Metrics: Semaglutide vs. Resmetirom in MASH Cohorts Alanine Aminotransferase (ALT) Reduction: -42.5% Mean Circulating Transaminase Reduction Evaluated Multi-Center Patient…
- Agenus Discloses Landmark Long-Term Survival Data for BOT+BAL Immuno-Oncology Regimen at SITC 2026 Demonstrating 51% 18-Month Survival in MSS Colorectal CancerKey Clinical Trial Metrics: BOT+BAL Regimen in Refractory MSS Colorectal Cancer Refractory MSS mCRC Patient Cohort: 123 Heavily Pretreated Patients (No Active Liver Mets) 18-Month Long-Term Survival…
- Imperial College Spinout OSSTEC Raises $8 Million for 3D Bone Implants as The Lancet Discloses Landmark Trial for Cardiovascular TherapyKey Clinical and Financial Benchmarks: OSSTEC Venture and Lancet Trial OSSTEC Series A Equity Financing Total: $8.0 Million USD (Innovate UK Co-Investment) Bio-Active Titanium Osseointegration Rate:…
- Washington State Confirms First US Avian Influenza Death of 2026 Linked to Dairy Cattle as Outbreak Hits 33 HerdsThe Centers for Disease Control and Prevention (CDC) and the Washington State Department of Health officially confirmed the first human fatality from avian influenza A(H5N1) in the United States in…
- American Heart Association and Harvard Trials Deconstruct Intermittent Fasting: Weight Loss Governed by Behavior Not MetabolismThe American Heart Association and the Harvard T.H. Chan School of Public Health published an extensive multi-center meta-review in early November 2026 deconstructing popular intermittent fasting…
- American Academy of Pediatrics Overhauls Pediatric Screen Guidelines Prioritizing Content Quality Over Arbitrary Time LimitsWhat Quantitative Benchmarks Anchor the AAP Pediatric Digital Guidelines? Adolescent Social Media Penetration: Approximately 92% active on digital networks Mean Age of First Mobile Device Access:…
- FDA Grants Priority Review to Regeneron's Cemdisiran for Myasthenia Gravis After Phase 3 NIMBLE Trial SuccessThe U.S. Food and Drug Administration granted Priority Review in early November 2026 to Regeneron Pharmaceuticals' investigational small interfering RNA (siRNA) therapeutic cemdisiran for adult…
- Teva Rolls Out Weltruza as First Once-Monthly Subcutaneous Olanzapine for Schizophrenia Free of 3-Hour PDSS MonitoringTeva Pharmaceuticals officially announced the widespread commercial deployment of Weltruza (olanzapine extended-release injectable suspension) for the treatment of adults with schizophrenia on…
- Roche Obtains FDA 510(k) Clearance for Cobas Eplex RP3 Respiratory Panel Detecting 19 Pathogens in Under 2 HoursRoche Diagnostics officially announced on November 6, 2026, that it has secured 510(k) market clearance from the United States Food and Drug Administration for its next-generation cobas eplex…
- FDA Accepts Resubmitted NDA for Rivoceranib Plus Camrelizumab in First-Line Liver Cancer Setting April 2027 PDUFA DateThe United States Food and Drug Administration formally accepted the resubmitted New Drug Application and Biologics License Application for the combination regimen of oral VEGFR inhibitor rivoceranib…
- FDA Investigates Severe Tumor and Malignancy Risks Linked to Novartis Zolgensma Gene TherapyHealth Regulators Scrutinize Vector Integration into Oncogenic GLI1 Gene Following Nine Documented Neoplasms in SMA Patients Investigating Regulatory Agency: U.S.
- FDA Clears Access MeMed BV Assay Providing 15-Minute Blood Test to Distinguish Bacterial and Viral InfectionsDiagnostic Turnaround Time: Generates quantified probability score within 15 minutes；Validated on Beckman Coulter DxI 9000 analyzers Approved Clinical Cohort: Adult and pediatric patients aged 90…
- PAHO Launches Five-Year Strategic Plan to Accelerate Malaria Elimination Across the AmericasOperational Horizon: 2026 through 2030 (Five-Year Implementation Cycle)；Spans 21 malaria-endemic nations in the Americas Strategic Vision: Achieve a "Zero Malaria Americas" regional status；Guides…
- PAHO Launches 4-Year Plan for Malaria Elimination in the Americas 2026-2030 in BrasiliaThe Pan American Health Organization (PAHO), serving as the Regional Office for the Americas of the World Health Organization (WHO), officially unveiled its landmark strategy document, the "Plan of…
- CDC Weekly Surveillance Reports US Measles Cases Surpassing 5,182 With Deaths in 3 StatesThe Centers for Disease Control and Prevention (CDC) released its latest nationwide infectious disease surveillance update on November 6, 2026, revealing that cumulative confirmed measles cases…
- FDA Grants Orphan Drug Designation to Octant's OCT-980 for Retinitis PigmentosaClinical-stage biotechnology enterprise Octant, Inc., a pioneer in high-throughput synthetic biology and multiplexed cellular drug discovery platforms, officially announced on November 6, 2026, that…
- CMS Releases CY 2027 Medicare Physician Fee Schedule and ASC Rules, Trimming Cataract Pay by 4%The Centers for Medicare & Medicaid Services (CMS) officially released its final policy changes and payment rates for the Calendar Year (CY) 2027 Medicare Physician Fee Schedule (MPFS) alongside the…
- Okogen Doses First Patient in Phase 1/2 EMERALD Trial of Treyegen for Acute Infectious ConjunctivitisClinical-stage biotechnology firm Okogen, Inc. announced on November 5, 2026, that the first patient has been officially dosed in the EMERALD trial, a pivotal multicenter Phase 1/2 clinical study…
- Nacuity Doses First Patient in Global Phase 3 Trial of Oral NPI-001 for Usher Syndrome Retinitis PigmentosaNacuity Pharmaceuticals, Inc., a clinical-stage ophthalmology biopharmaceutical enterprise dedicated to developing breakthrough treatments for blinding retinal diseases, announced on November 5,…
- FDA Approves Xbrane's Lucamzi (ranibizumab-blrz) Biosimilar to Lucentis for Wet AMDThe U.S. Food and Drug Administration (FDA) officially approved Lucamzi (ranibizumab-blrz), a high-quality biosimilar to reference biologic Lucentis (ranibizumab, developed by Genentech/Roche and…
- FX Shoulder Solutions Makes History with FDA 510(k) Clearance for Easytech Reversed Stemless SystemFX Shoulder Solutions, Inc., a rapidly expanding orthopedic medical technology innovator headquartered in Addison, Texas, officially announced on November 5, 2026, that it has received landmark…
- Altimmune Presents Landmark RECLAIM Phase 2 Data: Pemvidutide Drastically Reduces Heavy Drinking Days in AUDAltimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical leader advancing next-generation peptide therapeutics, officially presented comprehensive top-line data from its 24-week RECLAIM…
- Cloudbreak Pharma's CBT-001 Meets All Primary Endpoints in Pivotal Phase 3 Pterygium Eye Drop TrialCloudbreak Pharma Inc., a clinical-stage biopharmaceutical innovator headquartered in Irvine, California, officially announced positive top-line data from its global pivotal Phase 3 clinical trial…
- FDA Grants Fast Track Designation to Front Range Pharmaceuticals' FRP-003 for Long COVIDThe U.S. Food and Drug Administration's (FDA) Division of Rheumatology and Transplant Medicine granted Fast Track designation on November 6, 2026, to Front Range Pharmaceuticals' investigational oral…
- CMS Finalizes 2027 Medicare Physician Fee Schedule, Cutting Base Conversion Factor by 2.31%The Centers for Medicare & Medicaid Services (CMS) officially released its final rule for the Calendar Year 2027 Medicare Physician Fee Schedule (PFS) on November 4, 2026, implementing a 2.31%…
- UK NHS Launches World-First STRIDE-RCT Multi-Cancer Early Detection Blood Test Trial Across 200 Primary Care ClinicsDeploying Liquid Biopsy Platforms Across 200 Primary Care Hubs for Undifferentiated Symptoms In conventional clinical oncology, non-specific abdominal complaints—such as persistent bloating,…
- FDA Grants Accelerated Approval to J&J’s Rybrevant Faspro for Advanced Head and Neck CancerBispecific Subcutaneous Formulation Breaks Decade-Long Therapeutic Drought in Advanced HNSCC The landmark regulatory decision resolves a protracted decade-long therapeutic stagnation in post-platinum…
- Frequent and Unintentional Daytime Napping Linked to Higher Dementia Risk in Older AdultsResearchers at the Johns Hopkins Bloomberg School of Public Health found that frequent or unintentional daytime napping among older adults was associated with a higher risk of developing dementia…
- Study Suggests Drug-and-Vibration Approach May Help Move Proteins Out of the Brain, but It Is Not a Dementia TreatmentResearchers at the University of Oulu in Finland reported on Nov. 3 that an experimental combination of a blood-vessel-dilating drug and targeted whole-body vibration may increase the movement of…
- Long COVID Recovery Varies by Symptoms: About Half Improve by Year ThreeA three-year US follow-up study A study published in the Annals of Internal Medicine found that symptoms can continue to improve years after a person develops Long COVID, although improvement does…
- Energy Drinks Linked to More Cardiac-Arrest Reports in Young Adults, but Study Does Not Prove CauseA preliminary study from the American Heart Association found that reports of cardiac arrest appeared about 11 times more often in connection with caffeinated energy drinks and stimulant supplements…
- England Launches Multi-Cancer Blood-Test Trial for More Than 20,000 NHS Patients in Primary CareThe UK government has announced STRIDE-RCT, a clinical trial that will recruit more than 20,000 NHS patients through at least 200 general practices in England.
- CVS Plans to Separate Its Pharmacy and Insurance BusinessesA reversal of its integrated healthcare strategy One company would retain the CVS Health name and combine Aetna, pharmacy-benefit manager Caremark, Oak Street Health clinics, Signify Health home-care…
- FDA Classifies Recall of 3,744 Bottles of Combination Blood Pressure Drug as Class II After Dissolution Test FailureFDA Classifies Recall of 3,744 Bottles of Combination Blood Pressure Drug as Class II After Dissolution Test Failure The U.S.
- US Midterms Could Shift Sector Expectations, Putting AI, Energy and Healthcare in FocusUS Midterms Could Shift Sector Expectations, Putting AI, Energy and Healthcare in Focus The US midterm elections will determine control of Congress, but they may also change the regulatory, spending…
This section follows Google News sectioning, newest first; each article's category is shown in the tag next to its title.